Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published September 2017
  • Article
  • Info & Metrics
  • PDF
Loading

Modeling Secondary Mutations in BRCA1 and BRCA2

Dréan et al. Page 2022

PARP inhibitor (PARPi) resistance is often associated with “revertant” mutations that restore BRCA1 or BRCA2 gene function. Drean and colleagues used CRISPR-Cas9 mutagenesis to model these reversion mutations, finding that PARPi treatment selects for revertant clones in a Darwinian fashion. The periodicity of PARPi administration and the pre-treatment frequency of revertant tumour cells also influenced the clonal composition of tumours after treatment, suggesting that these factors should be taken into consideration when using these drugs. Nevertheless, revertant tumour cells retained the sensitivity to clinical WEE1 kinase inhibitors found in non-reverted cells, suggesting that despite the restoration of some BRCA gene function, therapeutic vulnerabilities might exist in PARPi resistant patients.

Cotargeting MEK and PDGFR/STAT3 Pathways to Treat PDAC

Sahu et al. Page 1729

The KRAS-driven MEK pathway is one of the key drivers of pancreatic cancer, however direct targeting using MEK inhibitors is insufficient to provide effective clinical benefit due to drug resistance. Using high-throughput 2D and novel 3D drug screens, Sahu and colleagues identified the compensatory feedback loop via the PDGFRα/STAT3/S6 pathways as the mechanism of resistance to MEK inhibitors. Combination treatment with a MEK inhibitor and the multi-kinase inhibitor ponatinib was effective in targeting pancreatic cancer cells by inhibiting both the MEK pathway and the compensatory PDGFRα/STAT3/S6 pathways. These results reveal a combination drug treatment strategy that may be effective in pancreatic cancer.

Tumor Vasculature-Targeted Enzyme Prodrug Therapy

Krais et al. Page 1855

This study takes a unique two-step therapeutic approach for treating breast tumors. Here, Krais and colleagues first target an enzyme to the tumor blood vessels followed by the administration of a non-toxic substrate that is converted to a cytotoxic agent by the tumor-bound enzyme. Additionally, this tumor vasculature targeting is further capitalized upon by combination with rapamycin to counter hypoxia-induced prosurvival signaling and combination with cyclophosphamide to exploit the release of tumor antigens caused by the enzyme prodrug therapy. The therapeutic combinations synergistically improve outcomes and warrant further studies of enzyme prodrug systems for cancer therapy.

A Potential Mechanism of ADC-induced Neutropenia

Zhao et al. Page 1866

Neutropenia is a common adverse event in cancer patients treated with antibody-drug conjugates (ADCs). Zhao and colleagues used an in vitro assay in which hematopoietic stem cells were differentiated to neutrophils to show that ADCs containing protease cleavable linkers can contribute to neutropenia via extracellular cleavage mediated by serine proteases secreted by differentiating neutrophils in bone marrow. The inhibitory effect on differentiating neutrophils was not mediated by internalization of ADCs either by macropinocytosis or FcγRs. These results provide more insight into the mechanism of action for ADC-induced neutropenia and will be helpful in the design of new ADCs with better therapeutic index.

  • ©2017 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 16 (9)
September 2017
Volume 16, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther September 1 2017 (16) (9) 1727;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther September 1 2017 (16) (9) 1727;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Modeling Secondary Mutations in BRCA1 and BRCA2
    • Cotargeting MEK and PDGFR/STAT3 Pathways to Treat PDAC
    • Tumor Vasculature-Targeted Enzyme Prodrug Therapy
    • A Potential Mechanism of ADC-induced Neutropenia
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement